IL17A and neoplasm: Both sPD‐L1 and IL‐17A had no significant difference in subgroup analysis based on age, gender, HBV‐DNA, model for end‐stage liver disease score (MELD), albumin‐bilirubin grade (ALBI), degree of tumor differentiation and microvascular invasion (MVI) (Table S2).